The Researchers from MedUni Vienna, led by Wilfried Ellmeier from MedUni Vienna's Institute of Immunology, have now discovered, in an animal model that the family of histone deacetylases (HDACs) plays a major role in the development of the autoimmune disease- Multiple Sclerosis(MS). After the necessary follow-up studies, this could lead to a new approach to treating Multiple Sclerosis in the future. The results of the study were published in the Journal of Autoimmunity. Many preclinical studies using an animal model suggest that HDAC inhibitors could be effective in autoimmune diseases, but the potential therapeutic effects of broad-spectrum inhibitors are to some extent counterbalanced by serious side effects. This study indicates that the development and use of HDAC1-specific inhibitors, with potentially fewer side-effects than broad-spectrum inhibitors, could be a possible approach for treating MS. However, researchers also believe that a few more detailed studies are still required to clarify that.